Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?

Journal of Pharmacological and Toxicological Methods

Volumn 60, Issue 1, 2009, Pages 24-27

  Pugsley, Michael K ^a   Authier, Simon ^b   Towart, Rob ^c   Gallacher, David J ^c   Curtis, Michael J ^d  

^a Global Preclinical Toxicology/Pathology   (United States)

^b LAB Research Inc   (Canada)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

FDA; Jacketed external telemetry; Safety Pharmacology; Short QT syndrome; Torsades de pointes

Indexed keywords

1,3 DIHYDRO 5 (2 FLUOROPHENYL) 3 (1H INDOL 3 YLMETHYL) 1 METHYL 2H 1,4 BENZODIAZEPIN 2 ONE; AMOXICILLIN; BANZEL; BEPRIDIL; CISAPRIDE; ETOMIDATE; FENTANYL; HALOPERIDOL; JNJ 282; LEMAKALIM; POTASSIUM CHANNEL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM ION; PROPRANOLOL; RUFINAMIDE; TERFENADINE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR PARAMETERS; DRUG BLOOD LEVEL; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAPHY; FOCAL EPILEPSY; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART REPOLARIZATION; HUMAN; LENNOX GASTAUT SYNDROME; NONHUMAN; POTASSIUM CURRENT; PREDICTION; QT INTERVAL; QT PROLONGATION; SHORT QT INTERVAL; SHORT QT SYNDROME; SUDDEN DEATH; SYMPTOM; T WAVE; TORSADE DES POINTES;

ANIMALS; ARRHYTHMIAS, CARDIAC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; RISK FACTORS; TORSADES DE POINTES; TOXICITY TESTS;

EID: 68749121938     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.07.001     Document Type: Article

References (44)

1. Adeyemi O., Roberts S., Harris J., West H., Shome S., and Dewhurst M. QA interval as an indirect measure of cardiac contractility in the conscious telemeterised rat: Model optimisation and evaluation. Journal of Pharmacological & Toxicological Methods 60 (2009) 159-166 (this volume)
2. Authier S., Paquette D., Gauvin D., Sammut V., Fournier S., Chaurand F., et al. Video EEG in conscious non human primate using radiotelemetry and computerized analysis: Refinement of a SP model. Journal of Pharmacological & Toxicological Methods 60 (2009) 88-93 (this issue)
3. Anon. ICHS7A: Safety pharmacology studies for human pharmaceuticals. Federal Register 66 (2001) 36791-36792
4. Anon. ICH harmonized tripartite guideline S7B. Safety pharmacology assessment of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (2005). http://www.ich.org/cache/compo/276 Available at: http://www.ich.org/cache/compo/276-254-1.html
5. BANZEL® (rufinamide) Package Insert (2008), Eisai Co., Ltd. Woodcliff Lake, NJ 07677
6. Bjerregaard P., and Gussak I. Short QT syndrome: Mechanisms, diagnosis and treatment. Nature Clinical Practice Cardiovascular Medicine 2 2 (2005) 84-87
7. Bridgland-Taylor M.H., Hargreaves A.C., Easter A., Orme A., Henthorn D.C., Ding M., et al. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. Journal of Pharmacological and Toxicological Methods 54 (2006) 189-199
8. Cambridge & Whiting. Evaluation of the QA interval as an index of cardiac contractility in anaesthetised dogs: Responses to changes in cardiac loading and heart rate. Cardiovascular Research 20 (1986) 444-450
9. Cerrone M., Noujaim S., and Jalife J. The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation. Journal of Internal Medicine 259 (2006) 24-38
10. Cheng H.C., and Incardona J. Effects of FPL64176, DPI201106, Dofetilide, and Chromanol 293B in isolated rabbit and guinea pig hearts. Journal of Pharmacological & Toxicological Methods 60 (2009) 174-184 (this volume)
11. Chui R.W., Fosdick A., Conner R., Jiang J., Bruenner B.A., and Vargas H.M. Assessment of two external telemetry systems (PhysioJacket™ and JET™) in beagle dogs with telemetry implants. Journal of Pharmacological & Toxicological Methods 60 (2009) 58-68 (this issue)
12. Chiu R.W., and Vargas H.M. A comparison of three software platforms for automated ECG analysis. Journal of Pharmacological & Toxicological Methods 60 (2009) 28-38 (this issue)
13. Ks a relevant drug target?. Cardiovascular Research 61 4 (2006) 651-652
14. Ferrie C.D., and Patel A. Treatment of Lennox-Gastaut Syndrome (LGS). European Journal of Paediatric Neurology (2009) 10.1016/j.ejpn.2008.12.005
15. Gauvin D.V., Tilley L.P., Smith F.W., and Baird T.J. Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving laboratory beagle dog by remote radiotelemetry. Journal of Pharmacological and Toxicological Methods 53 (2006) 128-139
16. Guo L., and Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. Journal of Pharmacological & Toxicological Methods 52 (2005) 123-135
17. Gussak I., Brugada P., Brugada J., Wright R.S., Kopecky S.L., Chaitman B.R., et al. Idiopathic short QT interval: A new clinical syndrome?. Cardiology 94 (2000) 99-102
18. Guth B.D., Bass A.S., Briscoe R., Chivers S., Markert M., Siegl P.K.S., et al. Comparison of electrocardiographic analysis for risk of QT interval prolongation using Safety Pharmacology and Toxicological studies. Journal of Pharmacological & Toxicological Methods 60 (2009) 107-116 (this volume)
19. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., and Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological and Toxicological Methods 54 (2006) 116-129
20. Herlich, J.A., Taggart, P., Proctor, J., Stahle, P., Colis, R., Hall, L., et al., (in press). The non-GLP toleration/dose range finding study: Design and methodology used in an early Toxicology screening program. Proceedings of the Western Pharmacology Society, vol. 52.
21. Himmel H.M. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential. Journal of Pharmacological and Toxicological Methods 56 (2007) 145-158
22. Holzgrefe H.H., Cavero I., Gleason C.R., Warner W.A., Buchanan L.V., Gill M.W., et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. Journal Pharmacological Toxicological Methods 55 (2007) 159-175
23. Ks) and the repolarization reserve. Annals of Noninvasive Electrocardiography 12 (2007) 64-78
24. Jost N., Virág L., Bitay M., Takács J., Lengyel C., Biliczki P., et al. Restricting excessive cardiac action potential and QT prolongation: A vital role for IKs in human ventricular muscle. Circulation 112 (2005) 1392-1399
25. Lu H.R., Vlaminckx E., Hermans A.N., Rohrbacher J., Van Ammel K., Towart R., et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. British Journal of Pharmacology 154 (2008) 1427-1438
26. Markert M., Stubhan M., Mayer K., Trautmann T., Klumpp A., Schuler-Metz A., et al. Validation of the normal, freely moving Göttingen Minipig for Pharmacological safety testing. Journal of Pharmacological & Toxicological Methods 60 (2009) 79-87 (this issue)
27. McLean M.J., Schmutz M., Pozza M.F., and Wamil A. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia 46 (2005) 375
28. Miyazaki H., Watanabe H., Kitayama T., Nishida M., Nishi Y., Sekiya K., et al. QT PRODACT: Sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 523-529
29. Morita H., Wu J., and Zipes D.P. The QT syndromes: Long and short. Lancet 372 (2008) 750-763
30. Moscardo E., Fasdelli N., Giarola A., Tontodonati M., and Dorigatti R. Optimised Neurobehavioral observational battery for the integrated assessment of cardiovascular and neurobehavioral functions in the Beagle dog. Journal of Pharmacological & Toxicological Methods 60 (2009) 198-209 (this volume)
31. Norton K., Iacono G., and Vezina M. Assessment of the pharmacological effects of ionotropic drugs on left ventricular pressure and contractility: An evaluation of the QA interval as an indirect indicator of cardiac inotropism. Journal of Pharmacological & Toxicological Methods 60 (2009) 193-197 (this volume)
32. Patel C., and Antzelevitch C. Pharmacological approach to the treatment of long and short QT syndromes. Pharmacology & Therapeutics 118 (2008) 138-151
33. Prior H., McMahon N., Schofield J., and Valentin J.P. Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs. Journal of Pharmacological and Toxicological Methods (2009) 167-173 (this volume)
34. Pugsley M.K., Authier S., and Curtis M.J. Principles of Safety Pharmacology. British Journal of Pharmacology 154 (2008) 1382-1399
35. Roden D.M. Long QT syndrome: Reduced repolarization reserve and the genetic link. Journal of Internal Medicine 259 (2006) 59-69
36. Rogawski M. Diverse mechanisms of epileptic drugs in the development pipeline. Epilepsy Research 69 (2006) 273-294
37. Shah, R. R. (in press). Drug-induced QT interval shortening: Potential harbinger of pro-arrhythmia and regulatory perspectives. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2009.0091.x
38. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced arrhythmia: QT and TRIaD. Heart Rhythm 2 (2005) 758-772
39. Soloviev M.V., Hamlin R.L., Shellhammer L.J., Barrett R.M., Wally R.A., Birchmeier P.A., et al. Variations in hemodynamic parameters and ECG in healthy, conscious, freely moving telemetrized beagle dogs. Cardiovascular Toxicology 6 (2006) 51-62
40. Tattersall M.L., Dymond M., Hammond T., and Valentin J.P. Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. Journal of Pharmacological & Toxicological Methods 53 (2006) 11-19
41. Ks potassium channel: An overlooked cardiovascular liability in drug safety screening?. Journal of Pharmacological & Toxicological Methods 60 (2009) 1-10 (this issue)
42. Toyoshima S., Kanno A., Kitayama T., Sekiya K., Nakai K., Haruna M., et al. QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. Journal of Pharmacological Sciences 99 (2005) 459-471
43. Van Deuren B., Van Ammel K., Somers Y., Cools F., Straetemans R., van der Linde H.J., et al. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: A versatile in vivo model in Cardiovascular Safety Research. Journal of Pharmacological & Toxicological Methods 60 (2009) 11-23 (this issue)
44. Viskin S. The QT interval: Too long, too short or just right. Heart Rhythm 6 (2009) 711-715